Influência do ambiente na estrutura de tamanho e biomassa da Emerita brasiliensis (Schimitt, 1935) na praia Brava e Guarda do Embaú

Emerita brasiliensis is an important species of Brazilian macrofauna, they are inhabitants of the intertidal areas, and have important components that enable their use as biological indicators environmental. Therefore, the objective was to analyze the relationship between population and size of individuals of Eremita brasiliensis, comparing two beaches on the coast of Santa Catarina, being Praia brava in Itajaí, with an increasing level of urbanization and Guarda do Embaú Beach in Paulo Lopes, which has a stationary degree. The collections took place in March and September 2016, with the sample area parallel to the sand and intertidal strips for a systematic sampling observing the estimated time for low tide. For collection, a 20cm diameter PVC cylinder was used and buried at a depth of 20cm. The samples were arranged in a 0.5mm opening mesh and sent to the laboratory, where the organisms of the genus Emerita brasiliensis were separated and identified for the measurement of biomorphometric data, observing the lateral diameter and rostro-caudal length of the carapace. The biomass weighing was performed before and after the drying procedure, performed in a controlled temperature oven at 37ºC for 48 hours. For statistical analysis, the ANOVA test was used. Based on the individuals collected, it is observed Guarda do Embaú beach with more individuals when compared to Brava Beach. Statistical data show a significant difference between the months and the beaches, which is justified by the state of conservation of Guarda do Embaú beach, which remains static due to its low urbanization. Therefore, it is concluded that the difference between Emerita Brasiliensis communities is due to changes in local dynamics, such as anthropic trampling and sediment change. The results were not accurate due to the low number of samples, but are significant and relevant for further research

Early Treatment with Pegylated Interferon Lambda for Covid-19

Background: The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear. Methods: We conducted a randomized, controlled, adaptive platform trial involving predominantly vaccinated adults with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brazil and Canada. Outpatients who presented with an acute clinical condition consistent with Covid-19 within 7 days after the onset of symptoms received either pegylated interferon lambda (single subcutaneous injection, 180 μg) or placebo (single injection or oral). The primary composite outcome was hospitalization (or transfer to a tertiary hospital) or an emergency department visit (observation for >6 hours) due to Covid-19 within 28 days after randomization. Results: A total of 933 patients were assigned to receive pegylated interferon lambda (2 were subsequently excluded owing to protocol deviations) and 1018 were assigned to receive placebo. Overall, 83% of the patients had been vaccinated, and during the trial, multiple SARS-CoV-2 variants had emerged. A total of 25 of 931 patients (2.7%) in the interferon group had a primary-outcome event, as compared with 57 of 1018 (5.6%) in the placebo group, a difference of 51% (relative risk, 0.49; 95% Bayesian credible interval, 0.30 to 0.76; posterior probability of superiority to placebo, >99.9%). Results: were generally consistent in analyses of secondary outcomes, including time to hospitalization for Covid-19 (hazard ratio, 0.57; 95% Bayesian credible interval, 0.33 to 0.95) and Covid-19-related hospitalization or death (hazard ratio, 0.59; 95% Bayesian credible interval, 0.35 to 0.97). The effects were consistent across dominant variants and independent of vaccination status. Among patients with a high viral load at baseline, those who received pegylated interferon lambda had lower viral loads by day 7 than those who received placebo. The incidence of adverse events was similar in the two groups. Conclusions: Among predominantly vaccinated outpatients with Covid-19, the incidence of hospitalization or an emergency department visit (observation for >6 hours) was significantly lower among those who received a single dose of pegylated interferon lambda than among those who received placebo